Linguamatics logo

award-winning natural language processing based text mining for life science and healthcare

Software Development
Cambridge, cambridgeshire
Founded in 2001
51-200 employees

linguamatics, an iqvia company, is the world leader in deploying innovative natural language processing (nlp)-based text mining for high-value knowledge discovery, information extraction and decision support. linguamatics nlp is used by leading hospitals, the u.s. food and drug administration (fda), premier academic institutions and 18 of the top 20 global pharmaceutical companies. i2e can be used to mine a wide variety of text resources, such as scientific literature, electronic health records, patents, clinical trials data, news feeds and proprietary content. i2e is available as an in-house enterprise system and a software-as-a-service (saas) on the cloud. typical applications in pharmaceuticals, biotechnology, healthcare, government and other sectors include: • mapping gene-disease relationships and identifying potentially novel therapeutic targets • biomarker discovery • drug repurposing • drug safety • mining electronic medical records to improve prediction of health outcomes • patent analysis • clinical trial site selection and study design • translational medicine • competitive intelligence • social media mining • sentiment analysis • idmp • qa of regulatory documents

Company Information

Industry
Software Development
Company Type
Privately Held
Founded
2001
Employee Range
51-200
Revenue Range
Not available

Location

Address
324 cambridge science park
City
Cambridge
Region
cambridgeshire
Postal Code
cb4 0wg
Country
United Kingdom

Specialties

Text Mining SoftwareText AnalyticsNatural Language Processing (nlp)Knowledge DiscoveryHealthcare AnalyticsClinical NlpInformation ExtractionPatent AnalysisArtificial Intelligence

Web Presence

Ready to automate your outreach?

Get unlimited access to our company database — complete with detailed profiles, funding info, and tech stacks — and start sending personalized emails with AI-powered follow-ups.